|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Isosorbide dinitrate#Adult Indications and Dosage]] |
| {{Isosorbide dinitrate}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| As noted under clinical pharmacology , multiple-dose studies with ISDN and other nitrates have shown that maintenance of continuous 24-hour plasma levels results in refractory tolerance. Every dosing regimen for isosorbide dinitrate tablets must provide a daily dose-free interval to minimize the development of this tolerance. With immediate-release ISDN, it appears that one daily dose-free interval must be at least 14 hours long.
| |
| | |
| As also noted under clinical pharmacology , the effects of the second and later doses have been smaller and shorter-lasting than the effects of the first.
| |
| | |
| Large controlled studies with other nitrates suggest that no dosing regimen with isosorbide dinitrate oral tablets should be expected to provide more than about 12 hours of continuous [[anti-anginal]] efficacy per day.
| |
| | |
| As with all titratable drugs, it is important to administer minimum dose which produces the desired clinical effect. The usual starting dose of isosorbide dinitrate tablets is 5 mg to 40 mg, two or three times daily. For maintenance therapy, 10 mg to 40 mg, two or three times daily is recommended. Some patients may require higher doses. A daily dose-free interval of at least 14 hours is advisable to minimize tolerance. The optimal interval will vary with the individual patient, dose and regimen.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ISORDIL (ISOSORBIDE DINITRATE) TABLET [BTA PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abb3ad49-73a8-49c5-adc5-164d052971d7 | publisher = | date = | accessdate = 30 January 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |